CY1112128T1 - Χρηση il-18bp ισομορφων για την αντιμετωπιση και/ή προληψη νευρολογικων φλεγμονωδων νοσων - Google Patents
Χρηση il-18bp ισομορφων για την αντιμετωπιση και/ή προληψη νευρολογικων φλεγμονωδων νοσωνInfo
- Publication number
- CY1112128T1 CY1112128T1 CY20111101178T CY111101178T CY1112128T1 CY 1112128 T1 CY1112128 T1 CY 1112128T1 CY 20111101178 T CY20111101178 T CY 20111101178T CY 111101178 T CY111101178 T CY 111101178T CY 1112128 T1 CY1112128 T1 CY 1112128T1
- Authority
- CY
- Cyprus
- Prior art keywords
- isoforms
- prevention
- treatment
- inflammatory diseases
- neurological inflammatory
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Marine Sciences & Fisheries (AREA)
- Cell Biology (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pyridine Compounds (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Η εφεύρεση σχετίζεται με τη χρήση μιας IL18-BP ισομορφής η οποία δεν δεσμεύεται σε IL18, ή ενός αγωνιστή αυτής, για αντιμετώπιση ή πρόληψη μιας νευρολογικής και/ή φλεγμονώδους νόσου. Προτιμητέες ισομορφές για χρήση στο πλαίσιο της παρούσας εφεύρεσης περιλαμβάνουν IL-18BPb και IL-18BPd.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05104863 | 2005-06-03 | ||
US68805705P | 2005-06-07 | 2005-06-07 | |
EP06763485A EP1888100B1 (en) | 2005-06-03 | 2006-06-02 | Use of il-18bp isoforms for the treatment and/or prevention of neurological inflammatory diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1112128T1 true CY1112128T1 (el) | 2015-11-04 |
Family
ID=35058651
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20111101178T CY1112128T1 (el) | 2005-06-03 | 2011-11-30 | Χρηση il-18bp ισομορφων για την αντιμετωπιση και/ή προληψη νευρολογικων φλεγμονωδων νοσων |
Country Status (17)
Country | Link |
---|---|
US (1) | US8128920B2 (el) |
EP (1) | EP1888100B1 (el) |
JP (1) | JP5048658B2 (el) |
AT (1) | ATE530227T1 (el) |
AU (1) | AU2006254106B2 (el) |
CA (1) | CA2610691C (el) |
CY (1) | CY1112128T1 (el) |
DK (1) | DK1888100T3 (el) |
ES (1) | ES2376534T3 (el) |
HR (1) | HRP20110788T1 (el) |
IL (1) | IL187839A (el) |
NO (1) | NO339540B1 (el) |
PL (1) | PL1888100T3 (el) |
PT (1) | PT1888100E (el) |
RS (1) | RS52192B (el) |
SI (1) | SI1888100T1 (el) |
WO (1) | WO2006128911A2 (el) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7968684B2 (en) | 2003-11-12 | 2011-06-28 | Abbott Laboratories | IL-18 binding proteins |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030105057A1 (en) * | 1997-03-19 | 2003-06-05 | Yale University | Methods and compositions for stimulating apoptosis and cell death or for inhibiting cell growth and cell attachment |
IL121860A0 (en) | 1997-08-14 | 1998-02-22 | Yeda Res & Dev | Interleukin-18 binding proteins their preparation and use |
JP4216950B2 (ja) * | 1998-09-01 | 2009-01-28 | 株式会社林原生物化学研究所 | インターロイキン−18結合蛋白質 |
CA2340579A1 (en) | 1998-09-01 | 2000-03-09 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Interleukin 18-binding protein |
PE20011350A1 (es) * | 2000-05-19 | 2002-01-15 | Vertex Pharma | PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE) |
AU2002224417A1 (en) * | 2000-10-18 | 2002-04-29 | Immunex Corporation | Methods for treating il-18 mediated disorders |
KR20040030625A (ko) * | 2001-05-25 | 2004-04-09 | 아레스 트레이딩 에스.에이. | Cns 손상을 치료하거나 예방하기 위한 il-18저해물질의 용도 |
JP5074030B2 (ja) | 2003-05-13 | 2012-11-14 | メルク セローノ ソシエテ アノニム | Il−18結合タンパク質の活性変異体とその医学的応用 |
-
2006
- 2006-06-02 JP JP2008514119A patent/JP5048658B2/ja active Active
- 2006-06-02 DK DK06763485.7T patent/DK1888100T3/da active
- 2006-06-02 AU AU2006254106A patent/AU2006254106B2/en active Active
- 2006-06-02 WO PCT/EP2006/062864 patent/WO2006128911A2/en active Application Filing
- 2006-06-02 CA CA2610691A patent/CA2610691C/en active Active
- 2006-06-02 PL PL06763485T patent/PL1888100T3/pl unknown
- 2006-06-02 ES ES06763485T patent/ES2376534T3/es active Active
- 2006-06-02 AT AT06763485T patent/ATE530227T1/de active
- 2006-06-02 US US11/915,913 patent/US8128920B2/en active Active
- 2006-06-02 RS RS20120014A patent/RS52192B/en unknown
- 2006-06-02 PT PT06763485T patent/PT1888100E/pt unknown
- 2006-06-02 SI SI200631215T patent/SI1888100T1/sl unknown
- 2006-06-02 EP EP06763485A patent/EP1888100B1/en active Active
-
2007
- 2007-12-03 IL IL187839A patent/IL187839A/en active IP Right Grant
- 2007-12-11 NO NO20076387A patent/NO339540B1/no unknown
-
2011
- 2011-10-27 HR HR20110788T patent/HRP20110788T1/hr unknown
- 2011-11-30 CY CY20111101178T patent/CY1112128T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
CA2610691C (en) | 2015-12-01 |
ES2376534T3 (es) | 2012-03-14 |
HRP20110788T1 (hr) | 2011-11-30 |
EP1888100B1 (en) | 2011-10-26 |
NO339540B1 (no) | 2016-12-27 |
PL1888100T3 (pl) | 2012-03-30 |
DK1888100T3 (da) | 2012-01-23 |
US8128920B2 (en) | 2012-03-06 |
IL187839A0 (en) | 2008-03-20 |
JP5048658B2 (ja) | 2012-10-17 |
US20080233085A1 (en) | 2008-09-25 |
AU2006254106B2 (en) | 2012-04-26 |
WO2006128911A2 (en) | 2006-12-07 |
JP2008542340A (ja) | 2008-11-27 |
WO2006128911A3 (en) | 2007-03-29 |
SI1888100T1 (sl) | 2012-01-31 |
AU2006254106A1 (en) | 2006-12-07 |
RS52192B (en) | 2012-10-31 |
CA2610691A1 (en) | 2006-12-07 |
PT1888100E (pt) | 2011-12-15 |
AU2006254106A8 (en) | 2008-04-03 |
IL187839A (en) | 2013-03-24 |
ATE530227T1 (de) | 2011-11-15 |
EP1888100A2 (en) | 2008-02-20 |
NO20076387L (no) | 2008-02-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1124144T1 (el) | Συνθεσεις και μεθοδοι για θεραπεια εγκεφαλικου επεισοδιου σε ενα υποκειμενο επι ταυτοχρονης θεραπειας στατινης | |
CY1123503T1 (el) | Απταμερη θεραπευτικα χρησιμα στην αντιμετωπιση των σχετικων με το συμπληρωμα διαταραχων | |
CY1111437T1 (el) | Τετραϋδροπυρρολοπυριμιδινοδιονες και η χρηση τους ως αναστολεων της ανθρωπινης ουδετεροφιλης ελαστασης | |
CY1118349T1 (el) | Παραγοντες συνδεσης me cd19 και χρησεις αυτων | |
CY1117678T1 (el) | Ενωσεις αναστολεων μεταλλοενζυμου | |
CY1118156T1 (el) | Ενωσεις αντιστροφης αμιδης ως αναστολεις δεακετυλασης πρωτεϊνων και μεθοδοι χρησης αυτων | |
CY1115871T1 (el) | Μεθοδοι για την αντιμετωπιση ουρικης αρθριτιδας | |
CY1118902T1 (el) | Ρυθμιση της δραστικοτητας των προνευροτροφινων | |
CY1114507T1 (el) | Συγχωνευμενη αμινο πυριδινη ως hsp90 αναστολεας | |
ATE476193T1 (de) | Immunstimulatorisches verfahren | |
CY1115059T1 (el) | Θεραπευτικα απταμερη χρησιμα στην θεραπευτικη αγωγη διαταραχων σχετιζομενων με συμπληρωμα | |
CY1116802T1 (el) | Ετεροκυκλικες ενωσεις | |
NO20082594L (no) | Pyrimidinylbenzotiofenforbindelser | |
CY1119800T1 (el) | Συνδυασμοι υποδοχεα της 5-ητ4 και αναστολεων ακετυλοχολινεστερασης για τη θεραπεια γνωστικων διαταραχων | |
ATE412414T1 (de) | 3,11b-cis-dihydrotetrabenazin zur behandlung von proliferativen krankheiten oder entzündungen | |
CY1115384T1 (el) | Αντι-φλεγμονωδης συνθεση | |
CY1113310T1 (el) | Εξανθρωπισμενα αντισωματα ειδικα για nogo-a και φαρμακευτικες χρησεις αυτων | |
CY1114497T1 (el) | ΜΕΘΟΔΟΙ ΚΑΙ ΣΥΝΘΕΣΕΙΣ ΓΙΑ ΤΗΝ ΑΝΤΙΜΕΤΩΠΙΣΗ ΚΑΙ ΤΗΝ ΠΡΟΛΗΨΗ ΝΟΣΟΥ ΠΟΥ ΣΧΕΤΙΖΕΤΑΙ ΜΕ ΤΗΝ ΙΝΤΕΓΚΡΙΝΗ ανβ5 | |
CY1114366T1 (el) | Συνθεσεις που περιεχουν αποαικoυορiνη και μεθοδοι χρησης τους | |
EA200501528A1 (ru) | Применение кластерина для лечения и/или профилактики периферических неврологических заболеваний | |
CY1117251T1 (el) | Μεθοδοι θεραπευτικης αντιμετωπισης της σκληροδερμιας | |
CY1117577T1 (el) | Υποκατεστημενα φουρανοκαρβοξαμιδια και χρηση αυτων | |
CY1112128T1 (el) | Χρηση il-18bp ισομορφων για την αντιμετωπιση και/ή προληψη νευρολογικων φλεγμονωδων νοσων | |
CY1116409T1 (el) | ΜΕΙΩΣΗ β-ΚΥΤΤΑΡΩΝ ΜΕ ΤΗ ΧΡΗΣΗ CD37-ΕΙΔΙΚΩΝ ΚΑΙ CD20-ΕΙΔΙΚΩΝ ΜΟΡΙΩΝ ΔΕΣΜΕΥΣΗΣ | |
CY1114825T1 (el) | Συνθεσεις και μεθοδοι αγωγης διαταραχων υπερπλασιας κυτταρων |